儿童急性哮喘发作口服全身皮质类固醇的系统综述与网状Meta分析
结果显示六种方案14天内复发率无显著差异,短期口服地塞米松可能作为较长疗程泼尼松龙的替代选择,但证据确定性低至极低。
要点
- 六种常用口服皮质类固醇方案在14天复发率上无显著差异。
- 短期地塞米松(0.3 mg/kg/天×1天)与泼尼松龙(1.0 mg/kg/天×3天)复发风险比RR 0.99(95%CI 0.56-1.74)。
- 证据确定性低至极低,临床决策需结合具体情况。
核心结论
- 儿童急性哮喘发作常用口服皮质类固醇方案疗效无显著差异。
- 短期口服地塞米松可能作为较长疗程泼尼松龙的替代选择。
研究设计与样本
- 系统综述与网状Meta分析,检索四个数据库至2024年3月。
主要发现
- 六种方案15项比较的14天内复发率均无显著差异。
- 地塞米松0.3 mg/kg/天×1天 vs 泼尼松龙1.0 mg/kg/天×3天:RR 0.99(95%CI 0.56-1.74)。
- 地塞米松0.6 mg/kg/天×2天 vs 泼尼松龙1.0-1.5 mg/kg/天×5天:RR 1.29(95%CI 0.84-1.98)。
- 纳入比较的证据确定性为低至极低。
关键数值与推荐
- 比较方案包括:地塞米松0.3 mg/kg/天×1天、0.6 mg/kg/天×1天、0.6 mg/kg/天×2天;泼尼松龙1.0 mg/kg/天×3天、1.0-1.5 mg/kg/天×5天、2.0 mg/kg/天×5天。
- 主要结局为14天内复发,定义为非计划急诊就诊或初级保健医生就诊。
临床怎么用
- 短期口服地塞米松可考虑作为较长疗程泼尼松龙的替代方案。
- 方案选择需结合证据确定性低至极低的情况个体化决策。
局限性
- 纳入比较的证据确定性为低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy differentials among corticosteroid regimens by type, dosage and duration, we conducted a systematic review and network meta-analysis of randomised controlled trials (RCTs). METHODS: We searched four databases from their inception to March 2024 and included RCTs that evaluated oral corticosteroids for asthma exacerbations in young people aged <21 years. We compared six regimens (dexamethasone (DEXA) 0.3 mg/kg/day administered for 1 day, DEXA 0.6 mg/kg/day for 1 day, DEXA 0.6 mg/kg/day for 2 days, prednisolone (PSL) 1.0 mg/kg/day for 3 days, PSL 1.0-1.5 mg/kg/day for 5 days and PSL 2.0 mg/kg/day for 5 days). Primary outcome was relapse within 14 days, defined as unplanned visit to an emergency department or primary care physician. RESULTS: Eleven studies involving 2353 patients were analysed in our quantitative synthesis. There were no significant differences in the relapse rates among 15 comparisons of six regimens. As part of the results, the network estimate showed that DEXA (0.3 mg/kg/day×1 day) compared with PSL (1.0 mg/kg/day for 3 days) had a risk ratio (RR) of 0.99 (95% CI 0.56 to 1.74), and DEXA (0.6 mg/kg/day for 2 days) compared with PSL (1.0-1.5 mg/kg/day×5 days) had an RR of 1.29 (95% CI 0.84 to 1.98). The certainty of the evidence for the included comparisons was low to very low. CONCLUSION: In this network meta-analysis, there were no significant differences in the efficacy of commonly used corticosteroid regimens for acute exacerbations in childhood asthma. Short-term oral DEXA may be an acceptable alternative to a longer course of PSL. PROSPERO REGISTRATION NUMBER: CRD 42023449189.
引用
- Amagasa S, Utsumi S, Okajima K, et al. Oral systemic corticosteroids in children with acute asthma exacerbations: a systematic review and network meta-analysis. Arch Dis Child. 2025. PMID: 40484453. doi:10.1136/archdischild-2024-327523
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。